Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DDX3X | O00571 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723394 | 0.87 | NPC1 (0.50) | CCKBRMEN1KMT2AGAAMAPT | |
| SCHEMBL1716149 | 0.81 | MAPT (0.46) | CNR1KDM4EMEN1KMT2AGAA | |
| SCHEMBL1715876 | 0.80 | TRPV1 (0.52) | KDM4EPOLBMEN1KMT2AMAPT | |
| SCHEMBL12459925 | 0.79 | GAA (0.40) | KDM4EKMT2AGAAMAPT | |
| SCHEMBL1715545 | 0.78 | TRPV1 (0.66) | — | |
| SCHEMBL1716188 | 0.76 | CCR3 (0.37) | MAPT | |
| SCHEMBL206358 | 0.72 | TRPV1 (0.58) | MGLLCNR1 | |
| SCHEMBL5130065 | 0.72 | MGLL (0.50) | MGLLCNR1GRIK1POLB | |
| SCHEMBL2734510 | 0.71 | TRPV1 (0.57) | MGLLCNR1GRIK1 | |
| SCHEMBL206493 | 0.70 | TRPV1 (0.56) | MGLLMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | claimed |
| JP-2007523888-A | — | — | 2007-08-23 | — | — | JP | claimed |
| EP-1685112-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005044802-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VRL ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-05-19 | — | — | WO | claimed |
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-7683076-B2 | Tetrahydro-quinolinylurea derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| EP-1685112-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044802-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VRL ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | NMUR1, OPRL1, HVCN1 | MGLL 4496/4885CNR1 64/4885MAPK14 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.